A comparison of low- and high-dose cisplatin-based combination chemotherapy as initial postoperative treatment in advanced ovarian adenocarcinoma

Joseph Menczer; Joseph Brenner; Michaela Modan; Gilad Ben-Baruch; Harry Brenner

doi:10.1016/0002-9378(86)90328-5

A comparison of low- and high-dose cisplatin-based combination chemotherapy as initial postoperative treatment in advanced ovarian adenocarcinoma

Joseph Menczer^*, Joseph Brenner, Michaela Modan, Gilad Ben-Baruch, Harry Brenner

^*Corresponding author for this work

Clinical Departments

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Cyclophosphamide, Adriamycin, and cisplatin were given as the initial postoperative treatment to 35 patients with Stages II through IV ovarian cancer of epithelial origin during two time periods. During the first period the dose of cisplatin was 60 mg/m² and during the second period it was 120 mg/m², while the dose of cyclophosphamide and Adriamycin remained unchanged. No differences with regard to survival, progression-free interval, rate, and outcome of second-look laparotomy between 18 consecutive patients who received the low-dose and 17 consecutive patients who received the high-dose cisplatin were observed. The complication rate was significantly higher in the high-dose treatment group. Low-dose cisplatin-based combination chemotherapy seems therefore to be the preferable initial postoperative treatment.

Original language	English
Pages (from-to)	974-979
Number of pages	6
Journal	American Journal of Obstetrics and Gynecology
Volume	155
Issue number	5
DOIs	https://doi.org/10.1016/0002-9378(86)90328-5
State	Published - Nov 1986

Keywords

Low-dose cisplatin
high-dose cisplatin
ovarian cardinoma

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/0002-9378(86)90328-5

Cite this

@article{4294332bccef4a20849a3f6e79e4e356,

title = "A comparison of low- and high-dose cisplatin-based combination chemotherapy as initial postoperative treatment in advanced ovarian adenocarcinoma",

abstract = "Cyclophosphamide, Adriamycin, and cisplatin were given as the initial postoperative treatment to 35 patients with Stages II through IV ovarian cancer of epithelial origin during two time periods. During the first period the dose of cisplatin was 60 mg/m2 and during the second period it was 120 mg/m2, while the dose of cyclophosphamide and Adriamycin remained unchanged. No differences with regard to survival, progression-free interval, rate, and outcome of second-look laparotomy between 18 consecutive patients who received the low-dose and 17 consecutive patients who received the high-dose cisplatin were observed. The complication rate was significantly higher in the high-dose treatment group. Low-dose cisplatin-based combination chemotherapy seems therefore to be the preferable initial postoperative treatment.",

keywords = "Low-dose cisplatin, high-dose cisplatin, ovarian cardinoma",

author = "Joseph Menczer and Joseph Brenner and Michaela Modan and Gilad Ben-Baruch and Harry Brenner",

year = "1986",

month = nov,

doi = "10.1016/0002-9378(86)90328-5",

language = "אנגלית",

volume = "155",

pages = "974--979",

journal = "American Journal of Obstetrics and Gynecology",

issn = "0002-9378",

publisher = "Elsevier Inc.",

number = "5",

}

TY - JOUR

T1 - A comparison of low- and high-dose cisplatin-based combination chemotherapy as initial postoperative treatment in advanced ovarian adenocarcinoma

AU - Menczer, Joseph

AU - Brenner, Joseph

AU - Modan, Michaela

AU - Ben-Baruch, Gilad

AU - Brenner, Harry

PY - 1986/11

Y1 - 1986/11

N2 - Cyclophosphamide, Adriamycin, and cisplatin were given as the initial postoperative treatment to 35 patients with Stages II through IV ovarian cancer of epithelial origin during two time periods. During the first period the dose of cisplatin was 60 mg/m2 and during the second period it was 120 mg/m2, while the dose of cyclophosphamide and Adriamycin remained unchanged. No differences with regard to survival, progression-free interval, rate, and outcome of second-look laparotomy between 18 consecutive patients who received the low-dose and 17 consecutive patients who received the high-dose cisplatin were observed. The complication rate was significantly higher in the high-dose treatment group. Low-dose cisplatin-based combination chemotherapy seems therefore to be the preferable initial postoperative treatment.

AB - Cyclophosphamide, Adriamycin, and cisplatin were given as the initial postoperative treatment to 35 patients with Stages II through IV ovarian cancer of epithelial origin during two time periods. During the first period the dose of cisplatin was 60 mg/m2 and during the second period it was 120 mg/m2, while the dose of cyclophosphamide and Adriamycin remained unchanged. No differences with regard to survival, progression-free interval, rate, and outcome of second-look laparotomy between 18 consecutive patients who received the low-dose and 17 consecutive patients who received the high-dose cisplatin were observed. The complication rate was significantly higher in the high-dose treatment group. Low-dose cisplatin-based combination chemotherapy seems therefore to be the preferable initial postoperative treatment.

KW - Low-dose cisplatin

KW - high-dose cisplatin

KW - ovarian cardinoma

UR - http://www.scopus.com/inward/record.url?scp=0022975825&partnerID=8YFLogxK

U2 - 10.1016/0002-9378(86)90328-5

DO - 10.1016/0002-9378(86)90328-5

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

AN - SCOPUS:0022975825

SN - 0002-9378

VL - 155

SP - 974

EP - 979

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

IS - 5

ER -

A comparison of low- and high-dose cisplatin-based combination chemotherapy as initial postoperative treatment in advanced ovarian adenocarcinoma

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this